Virologic failure and second-line antiretroviral therapy in children in South Africa-the IeDEA Southern Africa collaboration

Journal of Acquired Immune Deficiency Syndromes

Volumn 56, Issue 3, 2011, Pages 270-278

  Davies, Mary Ann ^a   Moultrie, Harry ^b,c   Eley, Brian ^a   Rabie, Helena ^d   Van Cutsem, Gilles ^a,e   Giddy, Janet ^f   Wood, Robin ^a   Technau, Karl ^g   Keiser, Olivia ^h   Egger, Matthias ^h   Boulle, Andrew ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d STELLENBOSCH UNIVERSITY   (South Africa)

^e MÉDECINS SANS FRONTIÈRES   (Switzerland)

^f MCCORD HOSPITAL   (South Africa)

^g UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^h UNIVERSITY OF BERN   (Switzerland)

Author keywords

antiretroviral therapy; children; resource limited setting; second line therapy; virologic failure

Indexed keywords

EFAVIRENZ; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; RITONAVIR; STAVUDINE; ZIDOVUDINE;

ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROBABILITY; SOUTH AFRICA; TREATMENT DURATION; TREATMENT FAILURE; VERTICAL TRANSMISSION; VIROLOGY; VIRUS LOAD;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; DRUG MONITORING; FEMALE; HIV INFECTIONS; HUMANS; INFANT; MALE; NEVIRAPINE; PREGNANCY; RITONAVIR; SALVAGE THERAPY; SOUTH AFRICA; TREATMENT FAILURE; VIRAL LOAD;

EID: 79951814365     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182060610     Document Type: Article

References (38)

1. The KIDS-ART-LINC Collaboration. Low risk of death, but substantial program attrition, in pediatric treatment cohorts in sub-Saharan Africa. J Aquir Immune Defic Syndr. 2008;15:523-531.
2. WHO. Antiretroviral therapy of HIV infection in infants and children: towards universal access 2006. Available at: http://www.who.int/hiv/pub/ paediatric/infants/en/index.html. Accessed September 02, 2007.
3. Paediatric European Network for Treatment of Aids. PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection. 2008. Available at: http://www.pentatrials.org/guide09.pdf. Accessed November 01, 2009.
4. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in Pediatric HIV infection 2008. Available at: http://AIDSinfo.nih.gov. Accessed December 17, 2008.
5. Jittamala P, Puthanakit T, Chaiinseeard S, et al. Predictors of virologic failure and genotypic resistance mutation patterns in Thai children receiving non0nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Pediatr Infect Dis J. 2009;28:826-830.
6. Kamya MR, Mayanja-Kizza H, Kambugu A, et al. Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr. 2007;46:187-193. (Pubitemid 47482614)
7. Germanaud D, Derache A, Traore M, et al. Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali. J Antimicrob Chemother. 2010;65:118-124.
8. Ruel TD, Achan J, Charlebois E, et al. Sustained viremia is common among HIV-infected Ugandan children receiving antiretroviral therapy and not detected by WHO CD4 criteria. Paper presented at: 18th International AIDS Conference, Vienna, Austria; July 18-23, 2011.
9. Emmett SD, Cunningham C, Mmbaga BT, et al. Predicting virologic failure among HIV-1 infected children receiving antiretroviral therapy in Tanzania: a cross-sectional study. J Acquir Immune Defic Syndr. 2010;54:368-375.
10. Funk MB, Linde R, Wintergerst U, et al. Preliminary experiences with triple therapy including nelfinavir and two reverse transcriptase inhibitors in previously untreated HIV-infected children. AIDS. 1999;13:1653-1658. (Pubitemid 30015712)
11. Zhang F, Haberer JE, Zhao Y, et al. Chinese pediatric highly active antiretroviral therapy observational cohort: a 1-year analysis of clinical, immunologic, and virologic outcomes. J Acquir Immune Defic Syndr. 2007;46:594-598. (Pubitemid 350191053)
12. Sutcliffe CG, van Dijk JH, Bolton C, et al. Effectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan Africa. Lancet Infect Dis. 2008;8:477-489. (Pubitemid 352005822)
13. Janssens B, Raleigh B, Soeung S, et al. Effectiveness of highly active antiretroviral therapy in HIV-positive children: evaluation at 12 months in a routine program in Cambodia. Pediatrics. 2007;120:e1134-e1140. (Pubitemid 350085507)
14. Bock P, Boulle A, White C, et al. Provision of antiretroviral therapy to children within the public sector of South Africa. Trans R SocTrop Med Hyg. 2008;102:905-911.
15. Davies M, Keiser O, Technau K, et al. Outcomes of the South African National Antiretroviral Treatment (ART) programme for children- The IeDEA Southern Africa Collaboration. S Afr Med J. 2009;99: 730-737.
16. Fenner L, Brinkhof M, Keiser O, et al. Early mortality and loss to followup in HIV-infected children starting antiretroviral therapy in Southern Africa. J Acquir Immune Defic Syndr. 2010;54:524-532.
17. National Department of Health South Africa. Guidelines for the Management of HIV-Infected Children in South Africa. Vol 1. Pretoria, South Africa: Jacana; 2005.
18. Ren Y, Nuttall J, Egbers C, et al. Effet of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis. J Acquir Immune Defic Syndr. 2008;47:566-569. (Pubitemid 351442016)
19. Chadwick E, Capparelli EV, Yogev R, et al. Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week results. AIDS. 2008;22:249-255.
20. Jackson DJ, Chopra M, Doherty TM, et al. Operational effectiveness and 36 week HIV-free survival in the South African programme to prevent mother-to-child transmission of HIV-1. AIDS. 2007;19:509-516.
21. National Department of Health South Africa. National Antiretroviral Treatment Guidelines. Pretoria, South Africa: Jacana; 2004.
22. Coetzee D, Hilderbrand K, Boulle A, et al. Effectiveness of the first district-wide programme for the prevention of mother-to-child transmission of HIV in South Africa. Bull World Health Organ. 2005;83: 489-494. (Pubitemid 41003323)
23. WHO. Scaling up Antiretroviral Therapy in Resource-Limited Settings: Treatment Guidelines for a Public Health Approach, 2003 Revision. Geneva, Switzerland: WHO; 2004.
24. WHO. Interim WHO clinical staging of HIV/AIDS and HIV/AIDS case definitions for surveillance 2005; Available at: www.who.int/hiv/pub/ guidelines/clinicalstaging.pdf. Accessed August 05, 2007.
25. StevensW,Wiggill T, Horsfield P, et al. Evaluation of the NucliSensEasyQ assay in HIV-1-infected individuals in South Africa. J Virol Methods. 2005;124:105-110. (Pubitemid 40138785)
26. WHO. The WHO child growth standards 2007. Available at: http:// www.who.int/childgrowth/en/. Accessed November 23, 2008.
27. Orrell C, Walensky R, Losina E, et al. HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. Antivir Ther. 2009; 14:523-531.
28. Lee KJ, Lyall H,Walker AS, et al. Wide disparity in switch to second-line therapy in HIV infected children in CHIPS. 2006. Paper presented at: Eighth International Congress on Drug Therapy in HIV infection; November 12, 2006; Glasgow, United Kingdom.
29. Scherpbier HJ, Bekker V, Van Leth F, et al. Long-term experience with combination antiretroviral therapy that contains nelfinavir for up to 7 years in a pediatric cohort. Pediatrics. 2006;117:e528-e536. (Pubitemid 46063193)
30. Nachega JB, Hislop M, Dowdy DW, et al. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med. 2007;146:564-573. (Pubitemid 351650537)
31. Boulle A, Van Cutsem G, Cohen K, et al. Outcomes of nevirapineand efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA. 2008;300:530-539.
32. Arrive E, Newell ML, Ekouevi DK, et al. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int J Epidemiol. 2007;36: 1009-1021. (Pubitemid 350018545)
33. Palumbo P, Lindsey JC, Hughes MD, et al. Antiretroviral treatment for children with peripartum nevirapine exposure. N Engl J Med. 2010;363: 1510-1520.
34. Van Zyl GU, Van der Merwe L, Cotton M, et al. Protease-inhibitor resistance in South African children exposed to ritonavir as single protease inhibitor compared to a lopinavir/ritonavir regimen. Paper presented at: IAS; 2009; Cape Town, South Africa.
35. Davies M, Boulle A, Fakir T, et al. Adherence to antiretroviral therapy in young children in Cape Town, South Africa. BMC Pediatr. 2008;8.
36. PENPACT1. A phase II/III randomised, open-label trial of combination antiretroviral regimens and treatment-switching strategies in HIV-1- infected antiretroviral na?̈ve children. Paper presented at: 2nd International Workshop on HIV Pediatrics; 2010; Vienna, Austria.
37. PENPACT1. A phase II/III randomised, open-label trial of combination antiretroviral regimens and treatment-switching strategies in HIV-1- infected antiretroviral na?̈ve children. Paper presented at: IAS; 2010; Vienna, Austria.
38. Ford N, Calmy A. Improving first-line antiretroviral therapy in resourcelimited settings. Curr Opin HIV AIDS. 2010;5:38-47.